Sino Biopharmaceutical Limited (SBMFF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sino Biopharmaceutical Limited (SBMFF) trades at $0.651 with AI Score 54/100 (Grade B). Sino Biopharmaceutical Limited (SBMFF) is a prominent pharmaceutical company based in Hong Kong, specializing in research, development, and manufacturing of a wide… Market cap: $11.6B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for SBMFF: SBMFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SBMFF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SBMFF: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sino Biopharmaceutical Limited (SBMFF) Healthcare & Pipeline Overview
Sino Biopharmaceutical Limited (SBMFF) is a leading pharmaceutical conglomerate in China, known for its extensive portfolio of innovative and generic drugs across multiple therapeutic areas, including oncology and cardiology, supported by a robust R&D framework.
What Is the Investment Thesis for SBMFF?
Sino Biopharmaceutical Limited has a market capitalization of $11.6B and a P/E ratio of 30.4, reflecting its strong profitability with a profit margin of 7.4% and an impressive gross margin of 82.1%. The company's growth is driven by its extensive product range and ongoing investment in R&D, particularly in oncology and cardiovascular drugs, which are experiencing increasing demand in China due to rising health concerns. With a dividend yield of 1.91%, Sino Biopharmaceutical also offers returns to shareholders while maintaining a stable financial position. However, investors should be cautious of the regulatory landscape in the Chinese pharmaceutical sector, which may pose risks to market operations and profitability. The company’s ability to innovate and navigate these regulatory challenges will be key to sustaining its competitive advantage and achieving long-term growth.
Based on FMP financials and quantitative analysis
SBMFF Key Highlights
Market Cap of $11.6B indicating strong market presence in the pharmaceutical sector.
- P/E ratio of 30.4, reflecting investor confidence in future earnings growth.
- Profit margin of 7.4%, showcasing operational efficiency.
- Gross margin of 82.1%, significantly higher than industry averages, indicating strong pricing power.
- Dividend yield of 1.91%, providing income to investors.
Who Are SBMFF's Competitors?
SBMFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| KRTX Karuna Therapeutics | $329.83 | +0.03% | $12.6B | 46 |
| TECH Bio-Techne Corporation | $72.28 | -0.28% | $11.3B | 94 |
| HALO Halozyme Therapeutics, Inc. | $106.12 | -1.39% | $12.6B | 96 |
| CORT Corcept Therapeutics Incorporated | $121.05 | +1.71% | $13.1B | 96 |
| KRYS Krystal Biotech, Inc. | $343.34 | +3.16% | $10.1B | 99 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
| PTGX Protagonist Therapeutics, Inc. | $154.94 | -1.53% | $9.96B | 86 |
| RXDX Prometheus Biosciences, Inc. | $199.92 | +0.09% | $9.56B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SBMFF's Key Strengths?
Strong market presence in the Chinese pharmaceutical sector.
- Diverse product offerings across multiple therapeutic areas.
- Robust R&D capabilities driving innovation.
- High gross margins indicating strong pricing power.
What Are SBMFF's Weaknesses?
Exposure to regulatory changes in the Chinese pharmaceutical industry.
- Dependence on the domestic market for revenue.
- Potential challenges in expanding internationally.
- Limited brand recognition outside of China.
What Could Drive SBMFF Stock Higher?
Expansion of product offerings in oncology and cardiovascular drugs.
- Continued investment in R&D to enhance drug development capabilities.
- Strategic partnerships and collaborations to enter international markets.
- Launch of new healthcare services to diversify revenue streams.
- Monitoring and adapting to regulatory changes in the Chinese pharmaceutical sector.
What Are the Key Risks for SBMFF?
Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Rich valuation — a P/E of 30.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Regulatory changes that may impact drug approvals and market access.
- Intense competition from domestic and international pharmaceutical firms.
- Economic fluctuations that could affect healthcare spending.
- Supply chain disruptions that may impact production capabilities.
What Are the Growth Opportunities for SBMFF?
- Expansion into Oncology: The oncology market in China is projected to grow significantly, driven by increasing cancer prevalence and rising healthcare expenditures. Sino Biopharmaceutical's existing oncology products, such as Qingkeshu and Anxian, position the company to capture a larger market share. By 2028, the oncology drug market in China is expected to exceed $30 billion, providing substantial growth potential for Sino Biopharmaceutical.
- Diversification of Product Offerings: With a strong R&D focus, Sino Biopharmaceutical can expand its product portfolio to include more innovative therapies, particularly in high-demand areas like immunotherapy and personalized medicine.
- International Market Penetration: Sino Biopharmaceutical has opportunities to expand its presence in international markets, particularly in Southeast Asia and Europe, where demand for affordable and effective pharmaceuticals is growing. By establishing partnerships or joint ventures, the company can leverage its existing capabilities to enter these markets and enhance revenue streams.
- Healthcare Services Expansion: Beyond pharmaceuticals, Sino Biopharmaceutical's involvement in healthcare services, such as hospital operations and medical consultancy, presents a growth avenue. The global healthcare services market is expected to grow at a CAGR of 10% through 2027, providing Sino Biopharmaceutical with opportunities to diversify its revenue sources.
- Technological Advancements in R&D: The integration of advanced technologies such as AI and machine learning in drug discovery and development can enhance Sino Biopharmaceutical's R&D efficiency. By adopting these technologies, the company can reduce time-to-market for new drugs and improve its competitive positioning in the rapidly evolving biotech landscape.
What Are SBMFF's Competitive Advantages?
- Established brand reputation in the Chinese pharmaceutical market.
- Diverse product portfolio covering multiple therapeutic areas.
- Strong R&D capabilities leading to innovative drug development.
- Extensive distribution network within China and potential international markets.
- Ability to navigate regulatory challenges in the Chinese healthcare landscape.
What Does SBMFF Do?
Founded in 2000, Sino Biopharmaceutical Limited is headquartered in Wan Chai, Hong Kong, and has evolved into a significant player in the pharmaceutical sector, focusing on research and development. The company operates through three primary divisions: Modernised Chinese Medicines, Chemical Medicines, and Investment initiatives, along with miscellaneous operations. Its extensive product portfolio includes oncology medications such as Qingkeshu and Anxian, cardiovascular drugs like Kaina, and hepatitis treatments including Tianqingganmei. Additionally, Sino Biopharmaceutical manufactures orthopedic medicines, respiratory drugs, and parenteral nutrition solutions, showcasing its diverse therapeutic offerings. The company has expanded its operations beyond pharmaceuticals to include property management, retail distribution, optometry services, hospital operations, and medical consultancy, thereby positioning itself as a comprehensive healthcare provider. With over 24,000 employees, Sino Biopharmaceutical is committed to advancing healthcare solutions and addressing the growing medical needs within China and beyond.
What Products and Services Does SBMFF Offer?
- Research and develop a wide range of pharmaceutical products.
- Manufacture modernized Chinese medicines and chemical medicines.
- Provide healthcare services, including hospital operations and consultancy.
- Engage in property management and distribution of pharmaceutical goods.
- Develop and market health food and medical devices.
- Conduct optometry services and sell ophthalmic products.
How Does SBMFF Make Money?
- Generate revenue through the sale of pharmaceutical products across various therapeutic areas.
- Engage in healthcare services, including hospital operations and medical consultancy.
- Invest in R&D to develop innovative drugs, enhancing market competitiveness.
- Manage properties and retail pharmaceutical goods to diversify income streams.
- Manufacture and market health food and medical devices.
What Industry Does SBMFF Operate In?
The biotechnology industry in China is experiencing rapid growth, driven by increasing healthcare demands and government support for innovation. The market is projected to expand significantly, with a compound annual growth rate (CAGR) of over 15% expected in the coming years. Sino Biopharmaceutical Limited stands out in this competitive landscape, particularly against peers like Karuna Therapeutics (KRTX), by leveraging its extensive product portfolio and established distribution networks. As the Chinese government continues to invest in healthcare infrastructure and regulatory reforms, companies like Sino Biopharmaceutical are well-positioned to capitalize on these trends and enhance their market share.
Who Are SBMFF's Key Customers?
- Hospitals and healthcare providers seeking pharmaceutical products.
- Patients requiring medications for various therapeutic needs.
- Healthcare institutions looking for consultancy and management services.
- Retail pharmacies distributing pharmaceutical goods.
- Optometry clinics needing ophthalmic products.
Company Profile
Sino Biopharmaceutical Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hong Kong, HK. The company is led by CEO S. Y. Tse. SBMFF has traded publicly since 2010.
Sino Biopharmaceutical Limited Financial Trajectory
Sino Biopharmaceutical Limited (SBMFF) reported $7.13B in revenue for Q4 2025, reflecting 0.0% growth compared to the prior quarter. The company recorded a net loss of $522.6M, with diluted EPS of $-0.03. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SBMFF averaged $0.03 in diluted EPS.
How Sino Biopharmaceutical Limited Is Valued
Sino Biopharmaceutical Limited carries a market capitalization of $11.6B, placing it in the large-cap category. Relative to its peer group, SBMFF's quantitative score of 54/100 is below the peer average of 86/100.
Key Financial Metrics
Return on equity for Sino Biopharmaceutical Limited stands at 7.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.1%, showing how much profit it generates from its asset base. SBMFF trades at a trailing price-to-earnings ratio of 30.36, above the Healthcare sector average of ~23x. Its free cash flow yield is 9.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Sino Biopharmaceutical Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.68 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
Sino Biopharmaceutical Limited has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 31.9% below estimates on average.
Forward Outlook
Wall Street analysts project Sino Biopharmaceutical Limited revenue of about $36.51B for fiscal 2026, with EPS near $0.24. The estimate reflects 19 contributing analysts.
SBMFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market presence in the Chinese pharmaceutical sector.
- Diverse product offerings across multiple therapeutic areas.
- Robust R&D capabilities driving innovation.
- High gross margins indicating strong pricing power.
Bear Case
- Exposure to regulatory changes in the Chinese pharmaceutical industry.
- Dependence on the domestic market for revenue.
- Potential challenges in expanding internationally.
- Limited brand recognition outside of China.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $7.13B | -$523M | -$0.03 |
| Q3 2025 | $7.13B | -$523M | -$0.03 |
| Q2 2025 | $8.79B | $1.69B | $0.09 |
| Q1 2025 | $8.79B | $1.69B | $0.09 |
Based on FMP financials and quantitative analysis
SBMFF Latest News
No recent news available for SBMFF.
SBMFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SBMFF.
Price Targets
Wall Street price target analysis for SBMFF.
SBMFF MoonshotScore
What does this score mean?
The MoonshotScore rates SBMFF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: S. Y. Tse
CEO
S. Y. Tse has extensive experience in the pharmaceutical industry, having held various leadership roles since the founding of Sino Biopharmaceutical Limited. With a strong educational background in pharmacy and business management, he has guided the company through significant growth phases and strategic expansions.
Track Record: Under S. Y. Tse's leadership, Sino Biopharmaceutical has successfully expanded its product portfolio and increased its market share in the Chinese pharmaceutical sector. His strategic focus on R&D and diversification has positioned the company for sustained growth.
SBMFF OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier typically has less stringent reporting standards and may involve higher risks due to lower liquidity and visibility in the market.
- OTC Tier: OTC Other
- Higher volatility due to lower trading volumes.
- Less regulatory oversight compared to major exchanges.
- Increased risk of fraud or misleading information.
- Potential for limited access to capital markets.
- Verify the company's financial statements and disclosures.
- Assess the competitive landscape and market trends.
- Review regulatory compliance and approval processes.
- Evaluate the management team’s track record and experience.
- Monitor news and developments affecting the pharmaceutical industry.
- Established history and track record in the pharmaceutical industry.
- Transparency in financial reporting and disclosures.
- Active engagement with regulatory bodies and compliance.
- Positive reputation among healthcare professionals and institutions.
SBMFF Healthcare Stock FAQ
What does the AI Score mean for SBMFF?
SBMFF holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Sino Biopharmaceutical Limited (SBMFF) is a prominent pharmaceutical company based in Hong Kong, specializing in research, development, and manufacturing of a wide range of therapeutic drugs. …
What does Sino Biopharmaceutical Limited do?
Sino Biopharmaceutical Limited is a pharmaceutical company that specializes in the research, development, and manufacturing of a diverse range of therapeutic products. The company operates in various therapeutic areas, including oncology, cardiology, and hepatitis treatments, and also provides healthcare services, including hospital management and medical consultancy.
What are the main risks for SBMFF?
Sino Biopharmaceutical Limited faces several risks, including regulatory changes that could affect drug approvals and market access. Additionally, the company operates in a highly competitive environment, which could pressure pricing and market share. Economic fluctuations may also impact healthcare spending, while supply chain disruptions pose ongoing operational risks.
How does Sino Biopharmaceutical Limited navigate regulatory approval processes?
Sino Biopharmaceutical Limited has established a robust compliance framework to navigate regulatory approval processes effectively. The company actively engages with regulatory bodies in China, ensuring adherence to local guidelines and standards. Its experienced management team closely monitors changes in regulations to adapt its strategies accordingly, thereby facilitating timely approvals for new drugs.
What are the key factors to evaluate for SBMFF?
Sino Biopharmaceutical Limited (SBMFF) holds an AI score of 54/100 (moderate). P/E: 30.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SBMFF data refresh on this page?
SBMFF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SBMFF's recent stock price performance?
Sino Biopharmaceutical Limited (SBMFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market presence in the Chinese pharmaceutical sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SBMFF overvalued or undervalued right now?
Sino Biopharmaceutical Limited (SBMFF) trades at 30.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SBMFF before investing?
Before investing in Sino Biopharmaceutical Limited (SBMFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data sourced from company profile and financial metrics.